PLPiotr Lodziński

Piotr Lodziński

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Piotr Lodziński has a total of 176 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hepatic Steatosis in Pulsed Field Ablation for Atrial Fibrillation: Prevalence, Liver Marker Concordance and Acute Procedural Characteristics

    by Maria Boszko, Bartosz Krzowski, Michał Gawlik, Alicja Skrobucha, Julia Szydlik, Mateusz Wawrzeńczyk, Karolina Mitrzak, Kacper Rutkowski, Karolina Ignaczak, Monika Gawałko, et al.

    Background/Objectives: Hepatic steatosis and metabolic dysfunction-associated steatotic liver disease (MASLD) are cardiometabolic phenotypes relevant to atrial fibrillation (AF), but their prevalence and acute procedural relevance in pulsed field ablation (PFA) are poorly defined. We estimated the prevalence of hepato-renal index (HRI)-detected hepatic steatosis, assessed liver marker concordance, and explored acute procedural characteristics. Methods: In this single-centre prospective study, 99 consecutive eligible patients undergoing first-time PFA for AF underwent B-mode hepatic ultrasound. Hepatic steatosis was defined a priori as HRI ≥ 1.28, measured offline by an investigator blinded to clinical and procedural data. HRI-based MASLD-compatible phenotype, Hepatic Steatosis Index (HSI), BARD score, and Fibrosis-4 index were analysed as secondary liver markers. Results: HRI-detected hepatic steatosis was present in 62/99 patients (62.6%, 95% CI 52.8–71.5), and HRI-based MASLD-compatible phenotype in 55/99 (55.6%, 95% CI 45.7–65.0). Agreement between HRI and HSI was poor (Cohen’s κ = 0.01; prevalence-adjusted bias-adjusted κ +0.06; positive agreement 62%). Acute pulmonary vein isolation was achieved in all patients. First-pass isolation was high in both groups (91.9% vs. 81.1%; p = 0.124). Most procedural metrics were similar. Fluoroscopy dose was modestly higher in patients with steatosis (median 226 vs. 207 mGy; p = 0.035), but this exploratory signal was inconsistent across sensitivity analyses. In-hospital complications were infrequent (4/99, 4.0%). Conclusions: In first-time PFA patients with feasible HRI assessment, hepatic steatosis was common, liver marker classifications showed limited patient-level agreement, and acute procedural conduct showed no consistent steatosis-specific signal. Long-term rhythm durability requires dedicated follow-up.

  • Open Access

    Association of Permanent Atrial Fibrillation With Mortality and Heart Failure Progression in Low Thromboembolic Risk Patients

    by Kacper Rutkowski, Bartosz Krzowski, Paweł Balsam, Marcin Grabowski, Leszek Kraj, Cezary Maciejewski, Piotr Lodziński, Michał Peller

    Association of Permanent Atrial Fibrillation with Mortality and Heart Failure Progression in Low Thromboembolic Risk Patients - Article abstract #951355


  • Open Access

    Hemorrhagic Complications in Patients with Atrial Fibrillation Treated with Novel Oral Anticoagulants: Results from the CRAFT Study

    by Marek Styczkiewicz, Mateusz Wawrzeńczyk, Adam Sukiennik, Bartosz Krzowski, Cezary Maciejewski, Piotr Lodziński, Leszek Kraj, Grzegorz Opolski, Marcin Grabowski, Paweł Balsam, et al.

    Background/Objectives: Hemorrhagic complications are among the most common adverse events of anticoagulant therapy in patients with atrial fibrillation (AF). Non-vitamin K antagonist oral anticoagulants (DOACs) are known to be more effective than vitamin K antagonists (VKAs) in preventing thromboembolism. The aim was to identify clinical factors associated with hemorrhagic events in AF patients treated with DOACs and to develop a simple, clinically applicable bleeding risk score. Methods: Data were derived from the multicenter CRAFT trial (NCT02987062). We conducted a retrospective analysis of hospital records of 1435 AF patients (median age: 67 years; 44.8% female) treated with dabigatran or rivaroxaban. The main study endpoints were the occurrence of a bleeding episode, thromboembolic episode, or all-cause death during a mean four-year follow-up (1531 [1062–2140] days). Results: The rates of bleeding episodes, thromboembolic episodes, and all-cause death were 17.4%, 13.5%, and 23.9%, respectively. Nine factors were identified as predictors of bleeding complications: male sex, history of major bleeding, history of cancer, COPD, CRT, rivaroxaban therapy, statin therapy, age, and absence of heart failure. Based on these, the CRAFT bleeding score was developed to predict the risk of hemorrhagic events in individual patients. Conclusions: The CRAFT bleeding score may be implemented in AF patients as an additional tool for evaluating DOACs safety prior to initiating anticoagulant therapy, and for guiding closer monitoring of high-risk individuals to minimize bleeding complications.

  • Open Access

    Smartphone app-based approximation of time spent with atrial fibrillation and symptoms in patients after catheter ablation: data from the TeleCheck-AF project

    by Emma Sandgren, Astrid N L Hermans, Monika Gawalko, Konstanze Betz, Afzal Sohaib, Chi Ho Fung, Henrike A K Hillmann, Rachel M J van der Velden, Dominique Verhaert, Daniel Scherr, et al.

    Reduction of atrial fibrillation (AF) burden is the preferred outcome measure over categorical AF rhythm recurrence after AF ablation. In this sub-analysis of the TeleCheck-AF project, we tested the feasibility of smartphone app-based approximation of time spent with AF and/or symptoms. Patients scheduled for at least one teleconsultation during the 12-month follow-up after AF ablation were instructed to use a smartphone photoplethysmography-based application for simultaneous symptom and rhythm monitoring three times daily for 1 week. Proxies of time spent with AF and/or symptoms (% recordings, load, and % days), temporal aggregation of AF and/or symptoms (density), and symptom–rhythm correlation (SRC) were assessed. In total, 484 patients (60% male, 62 ± 9.9 years) were included. Adherence, motivation, and patient satisfaction were high. %AF recordings, AF load, and %AF days (rs = 0.88–0.95) and %symptom recordings, symptom load, and %symptom days (rs = 0.95–0.98) showed positive correlations. The SRC correlated negatively with time spent with symptoms (rs = −0.65–0.90) and with time spent with AF (rs = −0.31–0.34). In patients with paroxysmal AF before ablation and AF during the monitoring period, 87% (n = 39/44) had a low-density score 90% (‘persistent AF pattern’). Corresponding numbers for patients with persistent AF before ablation were 48% (n = 11/23) and 43% (n = 10/23), respectively. On-demand, app-based simultaneous rhythm and symptom assessment provides objective proxies of time spent with AF and/or symptoms and SRC, which may assist in assessing AF and symptom outcomes after AF ablation.


  • Open Access

    Autoantibodies in Atrial Fibrillation—State of the Art

    by Joanna Zygadło, Grzegorz Procyk, Paweł Balsam, Piotr Lodziński, Marcin Grabowski, Aleksandra Gąsecka

    Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. To date, a lot of research has been conducted to investigate the underlying mechanisms of this disease at both molecular and cellular levels. There is increasing evidence suggesting that autoimmunity is an important factor in the initiation and perpetuation of AF. Autoantibodies are thought to play a pivotal role in the regulation of heart rhythm and the conduction system and, therefore, are associated with AF development. In this review, we have summarized current knowledge concerning the role of autoantibodies in AF development as well as their prognostic and predictive value in this disease. The establishment of the autoantibody profile of separate AF patient groups may appear to be crucial in terms of developing novel treatment approaches for those patients; however, the exact role of various autoantibodies in AF is still a matter of ongoing debate.


  • Open Access

    Administrative Data in Cardiovascular Research—A Comparison of Polish National Health Fund and CRAFT Registry Data

    by Cezary Maciejewski, Krzysztof Ozierański, Mikołaj Basza, Piotr Lodziński, Andrzej Śliwczyński, Leszek Kraj, Maciej Janusz Krajsman, Jefte Prado Paulino, Agata Tymińska, Grzegorz Opolski, et al.

    (1) Background: Administrative data allows for time- and cost-efficient acquisition of large volumes of individual patient data invaluable for evaluation of the prevalence of diseases and clinical outcomes. The aim of the study was to evaluate the accuracy of data collected from the Polish National Health Fund (NHF), from a researcher’s perspective, in regard to a cohort of atrial fibrillation patients. (2) Methods: NHF data regarding atrial fibrillation and common cardiovascular comorbidities was compared with the data collected manually from the individual patients’ health records (IHR) collected in the retrospective CRAFT registry (NCT02987062). (3) Results: Data from the NHF underestimated the proportion of patients with AF (NHF = 83% vs. IHR = 100%) while overestimating the proportion of patients with other cardiovascular comorbidities in the cohort. Significantly higher CHA2DS2VASc (Median, [Q1–Q3]) (NHF: 1, [0–2]; vs. IHR: 1, [0–1]; p < 0.001) and HAS-BLED (Median, [Q1–Q3]) (NHF: 4, [2–6] vs. IHR: 3, [2–5]; p < 0.001) scores were calculated according to NHF in comparison to IHR data, respectively. (4) Conclusions: Clinical researchers should be aware that significant differences between IHR and billing data in cardiovascular research can be observed which should be acknowledged while drawing conclusions from administrative data-based cohorts. Natural Language Processing of IHR could further increase administrative data quality in the future.


  • Open Access

    Patient motivation and adherence to an on-demand app-based heart rate and rhythm monitoring for atrial fibrillation management: data from the TeleCheck-AF project

    by Monika Gawałko, Astrid N L Hermans, Rachel M J van der Velden, Konstanze Betz, Dominique Vm Verhaert, Henrike A K Hillmann, Daniel Scherr, Julia Meier, Arian Sultan, Daniel Steven, et al.

    The aim of this TeleCheck-AF sub-analysis was to evaluate motivation and adherence to on-demand heart rate/rhythm monitoring app in patients with atrial fibrillation (AF). Patients were instructed to perform 60 s app-based heart rate/rhythm recordings 3 times daily and in case of symptoms for 7 consecutive days prior to teleconsultation. Motivation was defined as number of days in which the expected number of measurements (≥3/day) were performed per number of days over the entire prescription period. Adherence was defined as number of performed measurements per number of expected measurements over the entire prescription period. Data from 990 consecutive patients with diagnosed AF [median age 64 (57–71) years, 39% female] from 10 centres were analyzed. Patients with both optimal motivation (100%) and adherence (≥100%) constituted 28% of the study population and had a lower percentage of recordings in sinus rhythm [90 (53–100%) vs. 100 (64–100%), P < 0.001] compared with others. Older age and absence of diabetes were predictors of both optimal motivation and adherence [odds ratio (OR) 1.02, 95% coincidence interval (95% CI): 1.01–1.04, P < 0.001 and OR: 0.49, 95% CI: 0.28–0.86, P = 0.013, respectively]. Patients with 100% motivation also had ≥100% adherence. Independent predictors for optimal adherence alone were older age (OR: 1.02, 95% CI: 1.00–1.04, P = 0.014), female sex (OR: 1.70, 95% CI: 1.29–2.23, P < 0.001), previous AF ablation (OR: 1.35, 95% CI: 1.03–1.07, P = 0.028). In the TeleCheck-AF project, more than one-fourth of patients had optimal motivation and adherence to app-based heart rate/rhythm monitoring. Older age and absence of diabetes were predictors of optimal motivation/adherence.


  • Open Access

    Extracellular Vesicles in Atrial Fibrillation—State of the Art

    by Grzegorz Procyk, Dominik Bilicki, Paweł Balsam, Piotr Lodziński, Marcin Grabowski, Aleksandra Gąsecka

    Extracellular vesicles are particles released from cells and delimited by a lipid bilayer. They have been widely studied, including extensive investigation in cardiovascular diseases. Many scientists have explored their role in atrial fibrillation. Patients suffering from atrial fibrillation have been evidenced to present altered levels of these particles as well as changed amounts of their contents such as micro-ribonucleic acids (miRs). Although many observations have been made so far, a large randomized clinical trial is needed to assess the previous findings. This review aims to thoroughly summarize current research regarding extracellular vesicles in atrial fibrillation.


  • Open Access

    Is Increased Resting Heart Rate after Radiofrequency Pulmonary Vein Isolation a Predictor of Favorable Long-Term Outcome of the Procedure?

    by Cezary Maciejewski, Michał Peller, Piotr Lodziński, Edward Koźluk, Agnieszka Piątkowska, Dariusz Rodkiewicz, Izabela Sierakowska, Natalia Roman, Diana Wiśniewska, Dominika Żółcińska, et al.

    Background: Increased resting heart rate (RHR) after pulmonary vein isolation (PVI) for treatment of atrial fibrillation (AF) is a common observation, possibly resulting from ganglionated plexus modification during ablation. Previous trials have suggested that an increase in RHR after ablation might be related to higher efficacy of the procedure. The aim of this study was to determine whether or not higher increase in RHR after radiofrequency (RF) PVI might predict better long-term outcome of the procedure in a real-life cohort of patients in whom index ablation for paroxysmal AF was performed. Material and methods: The health records of patients who underwent index point-by-point or drag lesion RF PVI for paroxysmal AF in our department between January 2014 and November 2018 were analyzed. Resting heart rate (RHR) was determined from 12-lead ECG recorded prior to the ablation and before discharge to evaluate changes in RHR after PVI. Only patients in sinus rhythm before the procedure and at discharge were included in the analysis. Telephone follow-up was collected for evaluation of arrhythmia recurrence status. Results: A total of 146 patients who underwent PVI for paroxysmal AF were included. Mean follow-up time was 3.5 years. RHR increased from 64 [58.5–70], prior to procedure, to 72 [64.25–80] bpm at discharge (p < 0.001). Higher increase in RHR was not protective from arrhythmia recurrence in long-term observation in both univariable HR = 1.001 (CI 0.99–1.017, p = 0.857) and multivariable analyses HR = 1.001 (CI 0.99–1.02, p = 0.84). Conclusions: RHR after PVI increased in comparison to baseline in our cohort. However, we did not observe higher increase in RHR to be associated with more favorable long-term effectiveness of the procedure.


  • Open Access

    Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial

    by Paweł Balsam, Piotr Lodziński, Monika Gawałko, Leszek Kraj, Andrzej Śliwczyński, Cezary Maciejewski, Bartosz Krzowski, Agata Tymińska, Krzysztof Ozierański, Marcin Grabowski, et al.

    Background: We aimed to compare long-term outcomes in Polish patients with atrial fibrillation (AF) according to oral anticoagulation (OAC) type and to evaluate the predictive value of common thromboembolic and bleeding risk scores. Methods: Data from the CRAFT trial (NCT02987062) were included. The primary study endpoint was major adverse event (MAE; all-cause death, thromboembolic and hemorrhagic event) during the mean four-year follow-up period. Results: Out of 2983 patients with available follow-up data, 1686 (56%) were prescribed with vitamin K antagonist (VKA), 891 (30%) with rivaroxaban and 406 (14%) with dabigatran. Predominance of elderly and female patients with previous history of thromboembolic and hemorrhagic events was observed within rivaroxaban (vs. other OAC) group. Higher rate of MAEs and its components was observed in patients on VKA followed by rivaroxaban as compared to patients on dabigatran (43% vs. 42% vs. 31%, p < 0.01). After group matching based on clinical characteristics, higher risk of hemorrhagic events in VKA (vs. dabigatran) and rivaroxaban (vs. dabigatran) group were observed. The available thromboembolic (CHA2DS2-VASs, ATRIA, R2CHADS2) and bleeding (HAS-BLED, ATRIA, ORBIT) risk scores showed poor prediction value. Conclusions: Despite no difference in the thromboembolic event rate, treatment with VKA and rivaroxaban was associated with a significant increase in the risk of hemorrhagic events.